← Leaderboards
Andrew D Mesecar
University Of Illinois At Chicago
$12,210,126
Attributed
$18,883,179
Total exposure
17
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,207,179 · 18
By mechanism
P30$10,601,767 · 3
R01$9,798,205 · 2
P01$3,292,194 · 3
U01$2,217,438 · 1
R42$717,990 · 1
U54$677,889 · 1
Top collaborators
- Susan C. Baker10 shared
- Arun K Ghosh4 shared
- Bruce T Lamb1 shared
- Adrian Lynn Oblak1 shared
- Alan D. Palkowitz1 shared
- Timothy I Richardson1 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Arun K Ghosh$14,662,368
- Kyuyeon Han$1,638,975
- Peter Buttrick$13,327,562
- Igor B Roninson$18,517,458
- Oliver Yu$1,994,729
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureProteinsPharmaceutical PreparationsBiochemicalDesignProgramsBaseCellsEnzymesComplexPeptide HydrolasesKineticsResearch PersonnelPolyproteinsSevere Acute Respiratory SyndromeMolecularViralAntiviral AgentsLeadUniversitiesRoentgen RaysReplicaseMemberPapain
Grant awards (55)
Optimization of SHIP1 Inhibitors for the Treatment of Alzheimer's Disease$2,217,438
U01 · FY2025 · AG
Cancer Center Support Grant$1,884,000
P30 · FY2025 · CA · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2025 · AI
Structural Biology & Biophysics Core (SBB)$677,889
U54 · FY2025 · AG · contact PI
Cancer Center Support Grant$1,860,000
P30 · FY2024 · CA · contact PI
Developmental Funds$154,099
P30 · FY2024 · CA · contact PI
Life Sciences Mass Spectrometry Facility (LSMSF-SR)$126,818
P30 · FY2024 · CA · contact PI
Cancer Center Support Grant$1,860,000
P30 · FY2023 · CA · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2023 · AI
Developmental Funds$154,099
P30 · FY2023 · CA · contact PI
Life Sciences Mass Spectrometry Facility (LSMSF-SR)$126,818
P30 · FY2023 · CA · contact PI
Cancer Center Support Grant$1,860,000
P30 · FY2022 · CA · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2022 · AI
Developmental Funds$154,099
P30 · FY2022 · CA · contact PI
Life Sciences Mass Spectrometry Facility (LSMSF-SR)$126,818
P30 · FY2022 · CA · contact PI
SARS-CoV-2 protease inhibitors for treating COVID-19$750,974
R01 · FY2021 · AI
Developmental Funds$154,099
P30 · FY2021 · CA · contact PI
Life Sciences Mass Spectrometry Facility (LSMSF-SR)$126,818
P30 · FY2021 · CA · contact PI
Cancer Center Support Grant$1,860,000
P30 · FY2020 · CA · contact PI
Developmental Funds$154,099
P30 · FY2020 · CA · contact PI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$705,182
R01 · FY2019 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$715,409
R01 · FY2018 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$730,847
R01 · FY2017 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$741,213
R01 · FY2016 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$765,583
R01 · FY2015 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$602,456
R01 · FY2014 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$712,986
R01 · FY2013 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$602,456
R01 · FY2012 · AI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$603,560
R01 · FY2011 · AI
CONFORMATIONAL CHANGES IN AN IMPORTANT E3 UBIQUITIN LIGASE COMPLEX$5,914
P41 · FY2011 · RR · contact PI
Mechanisms of viral proteases in coronavirus replication and pathogenesis$614,617
R01 · FY2010 · AI
Mechanistic & Crystallographic Studies of SARS Proteases$267,681
P01 · FY2009 · AI · contact PI
Structural Biology$248,749
P01 · FY2009 · CA · contact PI
Protein Expression and Purification$177,416
P01 · FY2009 · AI · contact PI
Mechanistic & Crystallographic Studies of SARS Proteases$260,103
P01 · FY2008 · AI · contact PI
Structural Biology$241,663
P01 · FY2008 · CA · contact PI
Protein Expression and Purification$172,422
P01 · FY2008 · AI · contact PI
Novel Organophosphorous Hydrolases for Decontamination$344,895
R42 · FY2007 · GM · contact PI
Mechanistic & Crystallographic Studies of SARS Proteases$261,129
P01 · FY2007 · AI · contact PI
Structural Biology$239,387
P01 · FY2007 · CA · contact PI
Protein Expression and Purification$181,501
P01 · FY2007 · AI · contact PI
Novel Organophosphorous Hydrolases for Decontamination$373,095
R42 · FY2006 · GM · contact PI
Mechanistic & Crystallographic Studies of SARS Proteases$236,986
P01 · FY2006 · AI · contact PI
Structural Biology$191,050
P01 · FY2006 · CA · contact PI
Protein Expression and Purification$162,823
P01 · FY2006 · AI · contact PI
Mechanistic &Crystallographic Studies of SARS Proteases$272,400
P01 · FY2005 · AI
Protein Expression and Purification$193,397
P01 · FY2005 · AI
Structural Biology$185,487
P01 · FY2005 · CA
POLYCHROMATIC STUDIES OF ORGANOPHOSPHORUS HYDROLASES$13,517
P41 · FY2005 · RR
Novel Organophosphorous Hydrolases for Decontamination$96,248
R41 · FY2004 · GM
STRUCTURAL MECHANISMS OF ENZYME CATALYSIS$9,962
P41 · FY2004 · RR
Macromolecular X-ray Structure Facility Instrumentation$346,385
S10 · FY2003 · RR
Small Molecule X-Ray Diffraction Instrumentation$273,800
S10 · FY2002 · RR
A Molecular Basis for Phytoestrogen Chemoprevention$77,935
R03 · FY2002 · CA
A Molecular Basis for Phytoestrogen Chemoprevention$77,935
R03 · FY2001 · CA